Though mTOR is a key pathway for cyst growth, mTOR inhibitors are not recommended for treating ADPKD because of various side effects noted in clinical trials, including interfering with normal recovery from injury (Torres et al., 2010). Here, MTOR is linked to autosomal dominant polycystic kidney disease.